Natco Pharma Increases Stake in Adcock Ingram Holdings to 49% Amid African Market Expansion Plans

Natco Pharma Increases Stake in Adcock Ingram Holdings to 49% Amid African Market Expansion Plans​

Natco Pharma Limited has approved an acquisition of additional shares in Adcock Ingram Holdings Proprietary Limited, aiming to increase its stake from 35.75% to 49%. This strategic move is part of the company’s efforts to expand its geographic footprint across South Africa and the African continent.

The investment for this share acquisition totals ZAR 1,814,741,312.50, which is equivalent to ₹1069 crores at the prevailing exchange rate, excluding certain associated transaction costs. To achieve the increased holding, Natco Pharma will acquire 19,618,825 shares of Adcock Ingram Holdings Proprietary Limited (AIHPL) at a price of ZAR 92.50, or ₹5.89 per share.

In addition to the AIHPL acquisition, the company has also planned an investment up to Rs. 1400 Crores into Natco Pharma South Africa Proprietary Limited, which is a wholly-owned subsidiary of the firm. The investment in this subsidiary is intended to facilitate entry into new geographies for growth and increased profitability.

Adcock Ingram Profile and Market Standing​

Adcock Ingram Holdings Proprietary Limited (AIHPL) is a major South African pharmaceutical company established in 1890. It operates across four segments: Prescription, Consumer, Over-the-counter (OTC), and Hospitals. AIHPL maintains a diverse portfolio of products, ranging from generic and branded formulations to critical-care hospital products and consumer home-care items.

The company is noted as the leader in the OTC pharmaceutical market and holds the status of being the largest supplier of hospital and critical care products in South Africa. Its extensive product range includes well-known household brands such as Panado, Allergex, Epi-max, CitroSoda, and Myprodol.

Financial Performance Overview​

AIHPL reported its topline at US$ 423 million, with an EBITDA of approximately US$ 59 million for the period ending nine months on March 31, 2026. Following this transaction, Natco Pharma will be recognizing a 49% share of Adcock Ingram’s profit after tax in its financial statements.

The turnover figures for Adcock Ingram Holdings Proprietary Limited across the last three years are detailed below:


The acquisition is projected to be completed before the end of July 2026.

NATCOPHARM Stock Price Movement​

Shares of Natco Pharma Limited are shedding value, trading down 0.5% at ₹979.2 as of 12:09 PM. The stock sees strong intraday activity, with shares totaling 415,298 traded in the live market.